Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Emmanuel BachyVincent CamusCatherine ThieblemontDavid SibonRené-Olivier CasasnovasLoic YsebaertGandhi DamajStéphanie GuidezGian Matteo PicaWon Seog KimSoon Thye LimMarc AndréAlejandro Martin Martin Garcia-SanchoMaría Jesus PeñarrubiaPhilipp Bernhard StaberJudith TrotmanAndreas HuettmannVittorio StefoniAlessandro RePhilippe GaulardMarie-Hélène Delfau-LarueLaurence de LevalMichel MeignanJu LiJudith TrotmanRichard DelaruePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The addition of romidepsin to CHOP did not improve PFS, response rates, nor overall survival and increased the frequency for grade ≥ 3 treatment-emergent adverse events. Ro-CHOP does not represent a significant advance in the standard of care for patients with previously untreated PTCL.